Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

Savi, 2005, Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate‐receptor antagonists for the prevention of atherothrombosis, Semin Thromb Hemost, 31, 174, 10.1055/s-2005-869523

Sugidachi, 2000, The in vivo pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist properties, Br J Pharmacol, 129, 1439, 10.1038/sj.bjp.0703237

Goto, 2006, Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5’‐diphosphate receptor stimulation and cyclic calcium signaling, J Am Coll Cardiol, 47, 155, 10.1016/j.jacc.2005.08.055

Cattaneo, 2003, The platelet P2Y receptors as targets for new antithrombotic drugs, J Thromb Haemost, 1, 1133, 10.1046/j.1538-7836.2003.00286.x

Steinhubl, 2002, Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial, JAMA, 288, 2411, 10.1001/jama.288.19.2411

Yusuf, 2001, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation, N Engl J Med, 345, 494, 10.1056/NEJMoa010746

Braunwald, 2002, J Am Coll Cardiol, 40, 1366, 10.1016/S0735-1097(02)02336-7

Smith, 2006, Circulation, 113, e166

Angiolillo, 2005, Identification of low responders to a 300‐mg clopidogrel loading dose in patients undergoing coronary stenting, Thromb Res, 115, 101, 10.1016/j.thromres.2004.07.007

Gurbel, 2003, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83

Gurbel, 2006, Drug insight: clopidogrel nonresponsiveness, Nat Clin Pract Cardiovasc Med, 3, 387, 10.1038/ncpcardio0602

Gurbel, 2005, The relation of dosing to clopidogrel responsiveness and the incidence of high post‐treatment platelet aggregation in patients undergoing coronary stenting, J Am Coll Cardiol, 45, 1392, 10.1016/j.jacc.2005.01.030

Mobley, 2004, Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization, Am J Cardiol, 93, 456, 10.1016/j.amjcard.2003.10.042

Muller, 2003, Prevalence of clopidogrel non‐responders among patients with stable angina pectoris scheduled for elective coronary stent placement, Thromb Haemost, 89, 783, 10.1055/s-0037-1613462

Ajzenberg, 2005, Enhanced shear‐induced platelet aggregation in patients who experience subacute stent thrombosis: a case‐control study, J Am Coll Cardiol, 45, 1753, 10.1016/j.jacc.2004.10.079

Barragan, 2003, Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator‐stimulated phosphoprotein phosphorylation, Catheter Cardiovasc Interv, 59, 295, 10.1002/ccd.10497

Cuisset, 2006, High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome, J Thromb Haemost, 4, 542, 10.1111/j.1538-7836.2005.01751.x

Gurbel, 2005, Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study, J Am Coll Cardiol, 46, 1827, 10.1016/j.jacc.2005.07.056

Gurbel, 2005, Platelet reactivity in patients and recurrent events post‐stenting: results of the PREPARE POST‐STENTING Study, J Am Coll Cardiol, 46, 1820, 10.1016/j.jacc.2005.07.041

Matetzky, 2004, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction, Circulation, 109, 3171, 10.1161/01.CIR.0000130846.46168.03

Asai, 2006, Platelet inhibitory activity and pharmacokinetics of prasugrel (CS‐747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans, Platelets, 17, 209, 10.1080/09537100600565551

Jakubowski, 2006, The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects, J Cardiovasc Pharmacol, 47, 377, 10.1097/01.fjc.0000210069.47205.c0

Jernberg, 2006, Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non‐responders compared with clopidogrel in aspirin‐treated patients with stable coronary artery disease, Eur Heart J, 27, 1166, 10.1093/eurheartj/ehi877

Matsushima, 2006, Platelet inhibitory activity and pharmacokinetics of prasugrel (CS‐747) a novel thienopyridine P2Y12 inhibitor: a multiple‐dose study in healthy humans, Platelets, 17, 218, 10.1080/09537100600565510

Brandt, 2007, A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation, Am Heart J, 153, 66.e9, 10.1016/j.ahj.2006.10.010

Sugidachi, 2007, The greater in vivo antiplatelet effects of prasugrel compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to clopidogrel’s active metabolite, J Thromb Haemost, 5, 1545, 10.1111/j.1538-7836.2007.02598.x

Rehmel, 2006, Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450, Drug Metab Dispos, 34, 600, 10.1124/dmd.105.007989

Caplain, 1999, Pharmacokinetics of clopidogrel, Semin Thromb Hemost, 25, 25

Lins, 1999, Pharmacokinetic profile of 14C‐labeled clopidogrel, Semin Thromb Hemost, 25, 29

Savi, 2000, Identification and biological activity of the active metabolite of clopidogrel, Thromb Haemost, 84, 891, 10.1055/s-0037-1614133

Kurihara, 2005, In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in active metabolite formation, Drug Metab Rev, 37, 99

Farid, 2007, Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently, Clin Pharmacol Ther, 81, 735, 10.1038/sj.clpt.6100139

Kirchheiner, 2005, Clinical consequences of cytochrome P450 2C9 polymorphisms, Clin Pharmacol Ther, 77, 1, 10.1016/j.clpt.2004.08.009

Desta, 2002, Clinical significance of the cytochrome P450 2C19 genetic polymorphism, Clin Pharmacokinet, 41, 913, 10.2165/00003088-200241120-00002

Weerakkody, 2007, Clopidogrel poor responders: an objective definition by Bayesian classification, Platelets, 18, 428, 10.1080/09537100701206790

Angiolillo, 2007, Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study, Circulation, 115, 708, 10.1161/CIRCULATIONAHA.106.667741

Hulot, 2006, Cytochrome P450 2C19 loss‐of‐function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 108, 2244, 10.1182/blood-2006-04-013052

Suh, 2006, Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel, CMAJ, 174, 1715, 10.1503/cmaj.060664

Angiolillo, 2006, Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel, Arterioscler Thromb Vasc Biol, 26, 1895, 10.1161/01.ATV.0000223867.25324.1a